Back to top

NeuroSense Hits Key TDP-43 Endpoint in Phase 2b ALS Trial, Advances Toward Phase 3

An announcement from Neurosense Therapeutics Ltd. ( ($NRSN) ) is now available. On June 29, 2026, NeuroSense reported that its Phase 2b PARADIGM tr...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE: